BioStem CEO reports major stock and option holdings
BioStem Technologies, Inc. disclosed the initial equity holdings of Chief Executive Officer and 10% owner Jason Matuszewski.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
BioStem Technologies, Inc. disclosed the initial equity holdings of Chief Executive Officer and 10% owner Jason Matuszewski. He directly holds 1,278,433 shares of common stock plus multiple option and RSU awards. These include options over 2,250,000 shares at an exercise price of $2.00 per share, which are fully vested and exercisable, and additional options over 198,807 and 40,427 shares at $10.05 and 440,529 shares at $5.50, vesting over time. He also holds RSUs covering 42,343, 116,550, and 363,636 shares that vest in quarterly installments over three years, each representing a contingent right to receive one share of common stock.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Matuszewski Jason
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| holding | Restricted Stock Units F6, F5 | -- | -- | -- |
| holding | Restricted Stock Units F6, F7 | -- | -- | -- |
| holding | Restricted Stock Units F6, F8 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,929,763 contracts (Direct);
Restricted Stock Units — 522,529 contracts (Direct);
Common Stock — 1,278,433 shares (Direct)
Footnotes (8)
- F1. These options are fully vested and exercisable.
- F2. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F3. These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F4. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F5. These restricted stock units vest in equal quarterly installments over 3 years from the grant date (September 15, 2024).
- F6. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F7. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
- F8. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
Direct common shares: 1,278,433 shares
Option exercise price: $2.00 per share
Underlying shares at $2.00: 2,250,000 shares
+5 more
8 metrics
Direct common shares
1,278,433 shares
Common Stock held directly following the reported holdings
Option exercise price
$2.00 per share
Stock Option (Right to Buy) expiring October 24, 2032 over 2,250,000 underlying shares
Underlying shares at $2.00
2,250,000 shares
Fully vested stock options with a $2.00 exercise price
Underlying shares at $10.05
198,807 shares
Stock options with $10.05 exercise price expiring March 17, 2035
Underlying shares at $5.50
440,529 shares
Stock options with $5.50 exercise price expiring February 11, 2036
RSUs grant 1
42,343 units
Restricted Stock Units vesting quarterly over 3 years from September 15, 2024
RSUs grant 2
116,550 units
Restricted Stock Units with 33% vested March 17, 2026, then quarterly over two years
RSUs grant 3
363,636 units
Restricted Stock Units with 33% vesting February 11, 2027, then quarterly over two years
Key Terms
Stock Option (Right to Buy), Restricted Stock Units, contingent right, vest in equal quarterly installments
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with exercise prices and expirations"
Restricted Stock Units financial
"security_title: "Restricted Stock Units" with vesting in equal quarterly installments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
vest in equal quarterly installments financial
"These restricted stock units vest in equal quarterly installments over 3 years"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options does the BioStem (BSEM) CEO hold according to this filing?
Jason Matuszewski holds options over 2,250,000 shares at $2.00 per share, fully vested and exercisable. He also has options over 198,807 and 40,427 shares at $10.05, and 440,529 shares at $5.50, each with stated expiration dates and vesting schedules.
How do the restricted stock units for BioStem (BSEM) CEO vest?
The filing states RSUs over 42,343, 116,550, and 363,636 shares vest in equal quarterly installments over three years. One grant began vesting September 15, 2024, and others have 33% vesting on specified one-year anniversaries, then quarterly thereafter.
What rights do the BioStem (BSEM) restricted stock units provide the CEO?
Each restricted stock unit represents a contingent right to receive one share of BioStem common stock. Actual shares are delivered as units vest over time, subject to the vesting schedules described in the compensation footnotes.
When do the BioStem (BSEM) CEO’s stock options expire?
Reported option expirations include October 24, 2032 for the $2.00 options, March 17, 2035 and October 13, 2035 for $10.05 options, and February 11, 2036 for $5.50 options. Each option series follows its own vesting schedule before expiration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates